First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents.
暂无分享,去创建一个
Simone Brogi | Giulia Chemi | Giuseppe Campiani | Giuseppe Biamonti | Sandra Gemma | G. Biamonti | Simone Brogi | M. Brindisi | S. Gemma | Giulia Chemi | G. Campiani | S. Butini | G. Valacchi | A. Pecorelli | Stefania Butini | Alessandra Pecorelli | Giuseppe Valacchi | A. Ramunno | Margherita Brindisi | Gloria Alfano | F. Focher | Erika Pambianchi | Anna Ramunno | Lida Savi | Erika Pambianchi | Paola Galatello | Giulia Compagnoni | Federico Focher | Paola Galatello | Lida Savi | G. Alfano | Giulia Compagnoni
[1] L. M. Espinoza-Fonseca,et al. The benefits of the multi-target approach in drug design and discovery. , 2006, Bioorganic & medicinal chemistry.
[2] R. Simon,et al. Transgenic Overexpression of Adenosine Kinase Aggravates Cell Death in Ischemia , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] L. Toth,et al. Nuclear Factor κB and Adenosine Receptors: Biochemical and Behavioral Profiling , 2011, Current neuropharmacology.
[4] B. Fredholm,et al. Adenosine signaling and function in glial cells , 2010, Cell Death and Differentiation.
[5] Simone Brogi,et al. Rational design of the first difluorostatone-based PfSUB1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.
[6] T. Hermann,et al. 2-Aminobenzoxazole ligands of the hepatitis C virus internal ribosome entry site. , 2014, Bioorganic & medicinal chemistry letters.
[7] Y. Na,et al. Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation. , 2016, European journal of medicinal chemistry.
[8] C. Behl,et al. Inhibition of glycogen synthase kinase 3β is involved in the resistance to oxidative stress in neuronal HT22 cells , 2004, Brain Research.
[9] K. Chopra,et al. Flavocoxid, dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, exhibits neuroprotection in rat model of ischaemic stroke , 2014, Pharmacology Biochemistry and Behavior.
[10] E. Novellino,et al. Development of novel cyclic peptides as pro-apoptotic agents. , 2016, European journal of medicinal chemistry.
[11] Ettore Novellino,et al. Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors. , 2008, Journal of medicinal chemistry.
[12] L. Polito,et al. 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease. , 2015, ACS chemical neuroscience.
[13] W. C. Still,et al. Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .
[14] P. Cohen,et al. The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.
[15] J. Coyle,et al. Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.
[16] S. Rajagopalan,et al. Modified methylenedioxyphenol analogs lower LDL cholesterol through induction of LDL receptor expression[S] , 2012, Journal of Lipid Research.
[17] E. Novellino,et al. Synthetic spirocyclic endoperoxides: new antimalarial scaffolds , 2015 .
[18] M. Pandey,et al. Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging , 2016, Theranostics.
[19] Simone Brogi,et al. Disease‐Modifying Anti‐Alzheimer's Drugs: Inhibitors of Human Cholinesterases Interfering with β‐Amyloid Aggregation , 2014, CNS neuroscience & therapeutics.
[20] Deyong Ye,et al. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake. , 2014, Bioorganic & medicinal chemistry letters.
[21] F. Rossi,et al. Neuroprotection: The Emerging Concept of Restorative Neural Stem Cell Biology for the Treatment of Neurodegenerative Diseases , 2011, Current neuropharmacology.
[22] E. Novellino,et al. Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. , 2014, Journal of medicinal chemistry.
[23] David S. Goodsell,et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..
[24] N. Ibrahim,et al. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease. , 2015, Pharmacological research.
[25] Simone Brogi,et al. Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking , 2015, Scientific Reports.
[26] H. Stark,et al. Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases , 2016, Front. Neurosci..
[27] Simone Brogi,et al. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease , 2017, Progress in Neurobiology.
[28] C. Pérez,et al. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. , 2011, Journal of medicinal chemistry.
[29] D. Arnold,et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases , 2006, Journal of Neuroimmunology.
[30] J. Andersen,et al. Oxidative stress in neurodegeneration: cause or consequence? , 2004, Nature Reviews Neuroscience.
[31] M. Mattson,et al. Class II G protein-coupled receptors and their ligands in neuronal function and protection , 2007, NeuroMolecular Medicine.
[32] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[33] D. Schubert,et al. The specificity of neuroprotection by antioxidants , 2009, Journal of Biomedical Science.
[34] E. Novellino,et al. Multifunctional cholinesterase and amyloid Beta fibrillization modulators. Synthesis and biological investigation. , 2013, ACS medicinal chemistry letters.
[35] V. Doze,et al. G-Protein-Coupled Receptors in Adult Neurogenesis , 2012, Pharmacological Reviews.
[36] G. Kim,et al. The Role of Oxidative Stress in Neurodegenerative Diseases , 2015, Experimental neurobiology.
[37] Simon Lovestone,et al. The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.
[38] H. Sies,et al. Oxidative stress: a concept in redox biology and medicine , 2015, Redox biology.
[39] P. Beart,et al. Oxidative stress: emerging mitochondrial and cellular themes and variations in neuronal injury. , 2010, Journal of Alzheimer's disease : JAD.
[40] R. Simon,et al. Downregulation of Hippocampal Adenosine Kinase after Focal Ischemia as Potential Endogenous Neuroprotective Mechanism , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[41] D. Boison. Adenosine Kinase: Exploitation for Therapeutic Gain , 2013, Pharmacological Reviews.
[42] E. Novellino,et al. Site‐directed Mutagenesis of Key Residues Unveiled a Novel Allosteric Site on Human Adenosine Kinase for Pyrrolobenzoxa(thia)zepinone Non‐Nucleoside Inhibitors , 2016, Chemical biology & drug design.
[43] C. Cervellati,et al. Oxidative challenge in Alzheimer's disease: state of knowledge and future needs , 2016, Journal of Investigative Medicine.
[44] Ana Martínez,et al. GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS , 2011, Front. Mol. Neurosci..
[45] E. Novellino,et al. Pyrrolo[1,5]benzoxa(thia)zepines as a new class of potent apoptotic agents. Biological studies and identification of an intracellular location of their drug target. , 2005, Journal of medicinal chemistry.
[46] H. Brückmann,et al. Polypharmacology of dopamine receptor ligands , 2016, Progress in Neurobiology.
[47] Maurizio Recanatini,et al. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. , 2007, Journal of medicinal chemistry.
[48] P. Reddy,et al. Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal. , 2017, Drug discovery today.
[49] Kunwoo Park,et al. Glycogen synthase kinase-3β activity plays very important roles in determining the fate of oxidative stress-inflicted neuronal cells , 2007, Brain Research.
[50] Simone Brogi,et al. Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation. , 2016, European journal of medicinal chemistry.
[51] E. Novellino,et al. Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition , 2016 .
[52] J. Borrell,et al. Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer's disease. , 2015, Mini reviews in medicinal chemistry.
[53] E. Novellino,et al. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. , 2009, Journal of medicinal chemistry.
[54] R. Friesner,et al. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .
[55] B. Bahr,et al. Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase – Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology , 2012, Neurotherapeutics.
[56] Simone Brogi,et al. Identification of novel fluorescent probes preventing PrPSc replication in prion diseases. , 2017, European journal of medicinal chemistry.
[57] E. Novellino,et al. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies. , 2016, Future medicinal chemistry.
[58] Simone Brogi,et al. Discovery and Cardioprotective Effects of the First Non-Peptide Agonists of the G Protein-Coupled Prokineticin Receptor-1 , 2015, PloS one.
[59] E. Novellino,et al. Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies. , 2011, Journal of medicinal chemistry.